tiprankstipranks
Magenta Therapeutics initiated with a Neutral at H.C. Wainwright
The Fly

Magenta Therapeutics initiated with a Neutral at H.C. Wainwright

H.C. Wainwright analyst Edward White initiated coverage of Magenta Therapeutics with a Neutral rating and no price target. The company halted pipeline development and strategic alternatives are being explored, the analyst tells investors in a research note. The firm believes Magenta’s cash per share of $1.85 could offer some upside to the stock price.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on MGTA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles